At SABCS, Jean Wright presented a new analysis from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trials, providing critical insights into the role of tamoxifen for patients with “good risk” ductal carcinoma in situ (DCIS) who did not receive radiation therapy (RT). The results highlight that tamoxifen use significantly reduced overall ipsilateral breast recurrence (IBR) from 19% to 11% and invasive IBR from 11% to 6%, reinforcing its value in reducing recurrence risk. However, no significant reduction was seen in DCIS recurrence or contralateral breast events.
While RT omission remains an option in this population, the findings highlight the importance of shared decision-making between patients and physicians when considering endocrine therapy. Ongoing research on molecular profiling could further refine treatment decisions.
For more details, check out the full study: https://lnkd.in/eMKfiwSq
A special thanks to all the dedicated researchers, clinicians, and patients who contributed to these landmark findings.
